8-K: Cabaletta Bio Advances Autoimmune Cell Therapy

Cabaletta Bio reported Q2 2025 financial results and significant progress in its rese-cel clinical program, including FDA alignment for a 2027 BLA submission in myositis and an extended cash runway.

Summary

• Cabaletta Bio announced financial results for the second quarter ended June 30, 2025, and provided a business update on its rese-cel clinical development program.
• Research and development expenses increased to $37.6 million for Q2 2025, up from $23.4 million for Q2 2024.
• General and administrative expenses increased to $8.3 million for Q2 2025, up from $6.9 million for Q2 2024.
• Net loss for Q2 2025 was $(45.1) million, compared to $(27.6) million for Q2 2024.
• Net loss per share for Q2 2025 was $(0.73), compared to $(0.56) for Q2 2024.
• Cash, cash equivalents, and short-term investments totaled $194.7 million as of June 30, 2025, an increase from $164.0 million as of December 31, 2024.
• The company's cash position is expected to fund its operating plan into the second half of 2026.
• Enrollment for registrational cohorts in the RESET-Myositis trial is on track to begin in the second half of 2025, targeting an anticipated 2027 Biologics License Application (BLA) submission for rese-cel in myositis.
• Five disease-specific cohorts in the RESET clinical development program are fully enrolled from over 70 clinical sites as of July 31, 2025, with expansion phase enrollment continuing.
• New clinical data presented at the EULAR 2025 Congress reinforced compelling clinical responses and a favorable risk-benefit profile for rese-cel across myositis, lupus, and systemic sclerosis patients, with nearly all patients off immunomodulatory medications and steroids.
• Cabaletta closed a public offering, generating approximately $94 million in net proceeds to support late clinical-stage development and commercial readiness activities for rese-cel.

Sentiment

Score: 8

Explanation: The filing indicates significant positive progress in clinical development, regulatory alignment, and financial stability. The FDA alignment for a registrational pathway and compelling clinical data are major de-risking events for a clinical-stage biotech. While expenses and net loss increased, this is expected for a company advancing multiple late-stage clinical programs, and the successful capital raise mitigates immediate financial concerns, extending the cash runway.

Positives

• Achieved FDA alignment on key design elements for two registrational cohorts in the RESET-Myositis trial, paving the way for a 2027 BLA submission.
• Presented compelling clinical data at EULAR 2025 Congress, showing deep B cell depletion and strong clinical responses in myositis, lupus, and systemic sclerosis patients, with most patients off immunomodulators and steroids.
• Successfully closed a public offering, raising approximately $94 million in net proceeds, which extends the cash runway into the second half of 2026.
• Enrollment in dermatomyositis, scleroderma, and myasthenia gravis trials has been robust, indicating strong clinical interest and progress.
• Advancing CMC commercial supply readiness and innovation activities, including transferring the commercial drug product process to Lonza, supporting future registrational enrollment.

Negatives

• Research and development expenses increased by 60.7% to $37.6 million for Q2 2025 compared to $23.4 million for Q2 2024.
• General and administrative expenses increased by 20.3% to $8.3 million for Q2 2025 compared to $6.9 million for Q2 2024.
• Net loss significantly widened to $(45.1) million for Q2 2025 from $(27.6) million for Q2 2024, reflecting increased operational burn.

Risks

• Risks related to regulatory filings and potential clearance of rese-cel.
• The risk that signs of biologic activity or persistence observed in early data may not inform long-term results.
• Cabaletta's ability to demonstrate sufficient evidence of safety, efficacy, and tolerability in its preclinical studies and clinical trials of rese-cel.
• The risk that results observed with similarly-designed constructs in academic publications are not indicative of the results achievable with rese-cel.
• Risks that modifications to trial design or approach may not have the intended benefits and that the trial design may need further modification.
• Risks related to clinical trial site activation, delays in enrollment generally, or enrollment rates that are lower than expected.
• Delays related to the assessment of clinical trial results.
• Risks related to unexpected safety or efficacy data observed during clinical studies.
• Risks related to volatile market and economic conditions and public health crises.
• Cabaletta's ability to retain and recognize the intended incentives conferred by Orphan Drug Designation and Fast Track Designation or other designations for its product candidates.
• Risks related to Cabaletta's ability to protect and maintain its intellectual property position.
• Risks related to fostering and maintaining successful relationships with Cabaletta's collaboration and manufacturing partners.
• Uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates.
• The risk that any one or more of Cabaletta's product candidates will not be successfully developed and/or commercialized.
• The risk that the initial or interim results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies.

Future Outlook

Cabaletta Bio plans to initiate enrollment in two open-label, single-arm, registrational myositis cohorts in the second half of 2025, aiming for a first BLA submission for rese-cel in myositis in 2027. The company anticipates further FDA meetings in 3Q25 for lupus, 4Q25 for systemic sclerosis, and 1H26 for myasthenia gravis to align on additional registrational cohort designs. Upcoming clinical data presentations include complete Phase 1/2 data from RESET-Myositis, initial dose data from RESET-PV, and initial clinical data from RESET-MG in 2H25, followed by complete Phase 1/2 data from RESET-SLE and RESET-SSc in 1H26. The company expects its current cash position to fund operations into the second half of 2026.

Management Comments

• Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta, stated, 'We achieved significant progress advancing rese-cel in the first half of 2025, including aligning with the FDA on a registrational pathway for rese-cel in myositis to support an anticipated 2027 first BLA submission.'
• Dr. Nichtberger also noted, 'We also presented new data that reinforce the therapeutic potential of rese-cel across several autoimmune diseases.'
• He added, 'As our early clinical data are emerging, enrollment in dermatomyositis, scleroderma and myasthenia gravis has been particularly robust.'
• Dr. Nichtberger expressed anticipation for 'building on this momentum by initiating the myositis registrational program, obtaining regulatory alignment on registrational pathways for two additional indications this year and presenting new clinical data at multiple scientific meetings in the second half of 2025, including complete Phase 1/2 data from RESET-Myositis as well as initial clinical data from RESET-PVTM evaluating rese-cel without pre-conditioning.'

Industry Context

Cabaletta Bio operates in the rapidly evolving field of cell therapies for autoimmune diseases, a significant area of unmet medical need. Its lead candidate, rese-cel, is an autologous CAR-T cell therapy designed to transiently deplete CD19-positive cells to 'reset' the immune system, aiming for durable responses without chronic therapy. This approach positions Cabaletta at the forefront of developing potentially curative treatments, differentiating it from traditional immunosuppressive therapies. The focus on multiple autoimmune indications (myositis, lupus, systemic sclerosis, myasthenia gravis, pemphigus vulgaris) demonstrates a broad platform strategy within the CAR-T space for autoimmunity, a relatively newer application compared to oncology.

Stakeholder Impact

• Shareholders: Potential for significant value appreciation due to positive clinical and regulatory milestones, but also dilution from the recent public offering.
• Patients: Increased hope for a potentially curative, durable treatment for severe autoimmune diseases like myositis, lupus, and systemic sclerosis.
• Employees: Continued employment and potential growth opportunities as the company advances its clinical programs and moves towards commercialization.
• Creditors: Improved financial stability and extended cash runway reduce immediate credit risk.
• Suppliers/Partners: Continued and potentially increased demand for manufacturing and clinical trial services as programs advance.

Next Steps

• Initiate enrollment in two open-label, single-arm, registrational myositis cohorts (approximately 15 patients each) in the second half of 2025.
• Present complete Phase 1/2 clinical data from the RESET-Myositis trial in the second half of 2025.
• Present initial dose data from the RESET-PV trial (evaluating rese-cel without preconditioning) in the second half of 2025.
• Present initial clinical data from the RESET-MG trial in the second half of 2025.
• Meet with the FDA to align on key registrational design elements for the RESET-SLE trial in 3Q25.
• Meet with the FDA to align on key registrational design elements for the RESET-SSc trial in 4Q25.
• Present complete Phase 1/2 clinical data from the RESET-SLE and RESET-SSc trials in the first half of 2026.
• Meet with the FDA to align on key registrational design elements for the RESET-MG trial in 1H26.
• Submit the first Biologics License Application (BLA) for rese-cel in myositis in 2027.

Key Dates

Recommendation

Cabaletta Bio has achieved critical milestones that significantly de-risk its lead asset, rese-cel. FDA alignment on a registrational pathway for myositis, coupled with compelling clinical data demonstrating deep B cell depletion and durable responses, positions the company favorably. The successful capital raise extends the cash runway, providing financial stability through key upcoming data readouts and regulatory interactions. While increased expenses are noted, they are typical for a clinical-stage biotech advancing multiple programs. The potential for a first-in-class curative cell therapy for autoimmune diseases presents a substantial long-term growth opportunity.

Keywords

Biotechnology, CAR-T, Autoimmune Disease, Myositis, Lupus, Systemic Sclerosis, Myasthenia Gravis, Cell Therapy, Clinical Trials, FDA, Rese-cel, Cabaletta Bio